NCT04049409View on ClinicalTrials.gov

Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

November 20, 2019

Study Completion Date

November 20, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

CMAB809

CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.

DRUG

Trastuzumab

Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Taizhou Mabtech Pharmaceutical Co.,Ltd

INDUSTRY

NCT04049409 - Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers | Biotech Hunter | Biotech Hunter